Skip to content
TrustList
Funding news

Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine

Editorial

By TrustList Editorial

Greenoaks and Sequoia Capital co-led the round with Alphabet investing again; two days later the AI drug discovery company announced a research collaboration with MSD.

About Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine

Isomorphic Labs raises $5 billion Series C to scale its AI drug design engine

17 November 2026: Isomorphic Labs, the Alphabet-backed company that designs medicines with AI, says it has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. Alphabet made what the company calls a continued significant investment, and the money goes into its drug design engine, IsoDDE, and the pipeline of drug candidates built with it.

Not yet independently verified. The round rests on Isomorphic Labs' own announcement of 17 November 2026, read on 20 November; its full news release is a PDF we have not read. The company states no valuation, and the quotes and earlier round sizes reported in the press are left out here. We will update this when it can be confirmed, and remove this note.

Who is in the round

Andreessen Horowitz (a16z) joins as a new investor alongside several others the announcement does not name. Every existing investor took part again:

  • Thrive Capital
  • MGX
  • GV and CapitalG, Alphabet's two investment arms
  • Temasek
  • the UK Sovereign AI Fund

The presence of the UK Sovereign AI Fund is the detail a British reader will notice. It puts British public money next to some of the largest private technology investors in a single company.

What the money is for

Isomorphic says the funding will speed up its scientific work and its own AI development. Two things are named. The first is IsoDDE, which the company describes as a modality-agnostic drug design engine made of foundational AI models, meaning it is meant to work across different kinds of drug rather than one chemical class. The second is the pipeline of therapeutic candidates designed with it.

The company gives no valuation, no revenue figure and no timetable for its first trials in the announcement.

A pharmaceutical partner two days later

On 19 November Isomorphic announced a strategic research collaboration with MSD, the name Merck & Co. uses outside the US and Canada. The deal combines Isomorphic's AI approach with what it calls MSD's rich proprietary data resources and deep discovery experience. No financial terms, target diseases or milestones are stated.

The pattern is familiar in AI drug discovery: the model builder brings the computation, the drug maker brings years of experimental data that no public set contains. For Isomorphic the value lies as much in the data as in any payment.

Where it sits in our catalogue

Isomorphic Labs does not yet have a listing with us. Our artificial intelligence company category lists 1,121 businesses, most of them selling software to other companies rather than developing medicines. For procurement teams the round matters mainly as a signal of how much capital is now going into AI built for one scientific field rather than general-purpose models.

Company profile on TrustList: Isomorphic Labs

Sources

Categories & features

TrustList Weekly

The week in software and IT, in one email

The news that matters to buyers, new rankings and our own research. Every Thursday, free, and easy to leave.

We will email you to confirm. Unsubscribe with one click in any issue. Privacy policy

You may be interested in